SecBot SecBot
8-K ·Filed Nov 12, 2026

ABUS

Arbutus Biopharma Corp
NEUTRAL
Impact 2/10
Horizonmonths Processed4d 19h ago SEC0001171843-26-007378
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for initiation of a Phase 2b trial for imdusiran and for further AB-101 Phase 1 data in cHBV patients. Cash runway should be assessed in next quarterly filing.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ABUS drug pipeline →

AB-101

● Neutral Named in this 8-K
Impact
Phase
Phase 1a/1b
Time to market
AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
Next catalyst
None dated

What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$4.03
T+0 close · Nov 12, 2026 · via day close
Latest settled
+1.49%
T+1 · $4.09
Vs SPY
+1.85%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $4.03entry
  2. T+1 · 4d ago +1.49%α +1.85% · $4.09
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arbutus Biopharma filed an 8-K posting an updated corporate presentation on its website. The presentation reviews clinical data for its HBV pipeline, including imdusiran and AB-101, and reports cash of $104.6M as of October 31, 2026. No new material financial or regulatory events were disclosed.

Key Facts

  • Filed 8-K on November 12, 2026 to post an updated corporate presentation
  • Cash and cash equivalents of $104.6M as of October 31, 2026
  • Pipeline includes imdusiran (siRNA) in Phase 2a and AB-101 (oral PD-L1 inhibitor) in Phase 1
  • Imdusiran Phase 2a data: 10 patients achieved functional cure; 46% (48/105) achieved functional cure or discontinued NA therapy
  • AB-101 Phase 1 data: 84.6% of evaluable subjects at 40 mg achieved 100% PD-L1 receptor occupancy
  • No related SAEs or safety-related discontinuations reported for imdusiran in repeat-dose cohorts

Financial Impact

Cash position of $104.6M as of October 31, 2026; no revenue or earnings data in filing

cash

Risk Factors

  • No new financial guidance or material business development disclosed
  • Clinical-stage biotech with no approved products; relies on future trial results and regulatory outcomes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-007378
Document: f8k_111226.htm0001171843-26-007378
Document: 0001171843-26-007378-index-headers.html0001171843-26-007378
Document: 0001171843-26-007378-index.html0001171843-26-007378
Document: 0001171843-26-007378.txt0001171843-26-007378

Track record

25 reports on ABUS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Viewing Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026